Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CFAP95 divergent transcript (CFAP95-DT)
- Target
- CFAP95-DT
- Molecular classification
- Long non-coding RNA (IncRNA), Non-coding RNA, Other
01
Overview
CFAP95 divergent transcript (CFAP95-DT), also known as C9orf135-AS1 and related names, is a human long non-coding RNA gene mapped to chromosome 9 (chr9:69817047-69820794, hg38 assembly)[1]. It does not encode a protein, but instead is classified as a divergent antisense RNA that is transcribed from a region near the CFAP95 gene, likely regulated in a head-to-head orientation characteristic of divergent transcripts[1][5]. No protein product, therapeutic targeting, or direct function has been reported for CFAP95-DT in current scientific sources or major annotation platforms as of 2024[1][5].
- Other names
- C9orf135-AS1C9orf135-DTC9orf135 antisense RNA 1 (head to head)C9orf135 divergent transcriptCFAP95-DT
02
Mechanism of action
Not applicable or unknown (no drugs target this lncRNA).
03
Biological functions
At present, specific biological functions for CFAP95-DT are not established in public databases or the literature. In general, divergent lncRNAs often regulate gene expression or chromatin structure, but no direct evidence links CFAP95-DT to such functions as of this writing.
04
Disease associations
None directly established. No disease associations are currently documented for CFAP95-DT in major gene or disease databases[5]. Some divergent lncRNAs are implicated in diseases, but no information links CFAP95-DT specifically.
05
Safety considerations
None reported; as a non-coding RNA with no known drug interactions or direct biological effect, there are no documented safety concerns.
Beyond the preview
Go deeper on CFAP95 divergent transcript (CFAP95-DT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CFAP95 divergent transcript (CFAP95-DT).